GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadimastem Ltd (XTAE:KDST) » Definitions » EV-to-EBITDA

Kadimastem (XTAE:KDST) EV-to-EBITDA : -2.38 (As of May. 16, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kadimastem EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kadimastem's enterprise value is ₪22.67 Mil. Kadimastem's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-9.53 Mil. Therefore, Kadimastem's EV-to-EBITDA for today is -2.38.

The historical rank and industry rank for Kadimastem's EV-to-EBITDA or its related term are showing as below:

XTAE:KDST' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.26   Med: -0.38   Max: 0.36
Current: -2.38

During the past 11 years, the highest EV-to-EBITDA of Kadimastem was 0.36. The lowest was -15.26. And the median was -0.38.

XTAE:KDST's EV-to-EBITDA is ranked worse than
100% of 457 companies
in the Biotechnology industry
Industry Median: 9.79 vs XTAE:KDST: -2.38

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Kadimastem's stock price is ₪4.889. Kadimastem's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-2.800. Therefore, Kadimastem's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Kadimastem EV-to-EBITDA Historical Data

The historical data trend for Kadimastem's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadimastem EV-to-EBITDA Chart

Kadimastem Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.65 -2.40 -4.13 -2.06 -2.84

Kadimastem Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.13 - -2.06 - -2.84

Competitive Comparison of Kadimastem's EV-to-EBITDA

For the Biotechnology subindustry, Kadimastem's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kadimastem's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kadimastem's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kadimastem's EV-to-EBITDA falls into.



Kadimastem EV-to-EBITDA Calculation

Kadimastem's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=22.672/-9.529
=-2.38

Kadimastem's current Enterprise Value is ₪22.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kadimastem's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-9.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kadimastem  (XTAE:KDST) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Kadimastem's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.889/-2.800
=At Loss

Kadimastem's share price for today is ₪4.889.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kadimastem's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-2.800.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Kadimastem EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kadimastem's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Kadimastem (XTAE:KDST) Business Description

Traded in Other Exchanges
Address
Pinchas Sapir 7, Weizmann Science Park, Nes-Ziona, ISR
Kadimastem Ltd is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. It is developing revolutionary regenerative therapies based on stem cells.

Kadimastem (XTAE:KDST) Headlines

No Headlines